Matching articles for "alteplase"
In Brief: A New Indication for Tenecteplase (TNKase)
The Medical Letter on Drugs and Therapeutics • April 28, 2025; (Issue 1727)
The tissue plasminogen activator (tPA) tenecteplase
(TNKase – Genentech) has been approved by the FDA
for treatment of acute ischemic stroke in adults. It
is the second tPA to be approved in the US for...
The tissue plasminogen activator (tPA) tenecteplase
(TNKase – Genentech) has been approved by the FDA
for treatment of acute ischemic stroke in adults. It
is the second tPA to be approved in the US for this
indication; alteplase (Activase) was approved in
1996. Tenecteplase was approved in 2000 to reduce
the risk of death associated with acute ST-elevation
myocardial infarction (STEMI).
Tenecteplase (TNKase) for Thrombolysis
The Medical Letter on Drugs and Therapeutics • November 13, 2000; (Issue 1092)
Tenecteplase, a recombinant variant of human tissue plasminogen activator, is now available for thrombolysis in patients with acute myocardial...
Tenecteplase, a recombinant variant of human tissue plasminogen activator, is now available for thrombolysis in patients with acute myocardial infarction.
Reteplase (Retavase)
The Medical Letter on Drugs and Therapeutics • February 28, 1997; (Issue 995)
Reteplase (Retavase - Boehringer Mannheim), a recombinant protein derivative of human tissue plasminogen activator (t-PA), has been marketed in the USA for thrombolysis in patients with acute myocardial...
Reteplase (Retavase - Boehringer Mannheim), a recombinant protein derivative of human tissue plasminogen activator (t-PA), has been marketed in the USA for thrombolysis in patients with acute myocardial infarction.
Anistreplase for Acute Coronary Thrombosis
The Medical Letter on Drugs and Therapeutics • February 23, 1990; (Issue 812)
Anistreplase (Eminase - SmithKline Beecham, Upjohn), a plasminogen activator also known as APSAC, was recently approved by the US Food and Drug Administration (FDA) for intravenous (IV) thrombolytic treatment...
Anistreplase (Eminase - SmithKline Beecham, Upjohn), a plasminogen activator also known as APSAC, was recently approved by the US Food and Drug Administration (FDA) for intravenous (IV) thrombolytic treatment of coronary thrombosis. Three other thrombolytic agents - intracoronary urokinase (Abbokinase) and intracoronary or intravenous streptokinase (Streptase; Kabikinase) and alteplase (TPA; Activase)- were previously approved for coronary thrombolysis (Medical Letter, 29:107, 1987).